Literature DB >> 1672253

c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.

W J Gullick1, S B Love, C Wright, D M Barnes, B Gusterson, A L Harris, D G Altman.   

Abstract

The c-erbB-2 gene is overexpressed in about 20% of human breast cancers. Four hundred and eighty-three cases previously examined by immunohistochemical staining for c-erbB-2 expression were analysed to assess the risk associated with the elevated protein expression. Oncoprotein expression was correlated with increasing tumour grade but not with oestrogen receptor status, nodal involvement, tumour size or age. There was an increased risk of relapse and death associated with c-erbB-2 expression irrespective of nodal involvement. This marker thus appears to be a significant prognostic factor in the early as well as the late stages of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1672253      PMCID: PMC1971853          DOI: 10.1038/bjc.1991.100

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

Authors:  M J van de Vijver; J L Peterse; W J Mooi; P Wisman; J Lomans; O Dalesio; R Nusse
Journal:  N Engl J Med       Date:  1988-11-10       Impact factor: 91.245

2.  Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease.

Authors:  D J Zhou; H Ahuja; M J Cline
Journal:  Oncogene       Date:  1989-01       Impact factor: 9.867

Review 3.  The protein kinase family: conserved features and deduced phylogeny of the catalytic domains.

Authors:  S K Hanks; A M Quinn; T Hunter
Journal:  Science       Date:  1988-07-01       Impact factor: 47.728

4.  Expression of the c-erbB-2 protein in normal and transformed cells.

Authors:  W J Gullick; M S Berger; P L Bennett; J B Rothbard; M D Waterfield
Journal:  Int J Cancer       Date:  1987-08-15       Impact factor: 7.396

5.  Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance.

Authors:  M Guérin; M Gabillot; M C Mathieu; J P Travagli; M Spielmann; N Andrieu; G Riou
Journal:  Int J Cancer       Date:  1989-02-15       Impact factor: 7.396

6.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

7.  Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.

Authors:  M S Berger; G W Locher; S Saurer; W J Gullick; M D Waterfield; B Groner; N E Hynes
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

8.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.

Authors:  W J Muller; E Sinn; P K Pattengale; R Wallace; P Leder
Journal:  Cell       Date:  1988-07-01       Impact factor: 41.582

9.  An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma.

Authors:  D M Barnes; G A Lammie; R R Millis; W L Gullick; D S Allen; D G Altman
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

10.  c-erbB-2 expression in benign and malignant breast disease.

Authors:  B A Gusterson; L G Machin; W J Gullick; N M Gibbs; T J Powles; C Elliott; S Ashley; P Monaghan; S Harrison
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

View more
  72 in total

1.  Flow Cytometric Assay of c-erbB-2 Protein in Fine Needle Aspirates of Fresh and Frozen Human Breast Cancer Tissues.

Authors: 
Journal:  Breast Cancer       Date:  1996-06-28       Impact factor: 4.239

2.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

3.  Her-2/neu expression as a predictive factor for response to anthracycline-based chemotherapy in a mexican population of locally advanced breast cancer patients.

Authors:  David Muñoz-Gonzalez; Isabel Zeichner-Gancz; Myrna Candelaria; Maria Teresa Ramirez-Ugalde; Manuel Perez-Sanchez; Guadalupe Cervantes-Vazquez; David Cantu-de Leon; Arcelia Mora-Tizcareño; Julio Leonor-Ortíz
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

4.  ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically- and immunohistochemically-determined hormone receptors.

Authors:  A A Keshgegian
Journal:  Breast Cancer Res Treat       Date:  1995-08       Impact factor: 4.872

5.  MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo.

Authors:  Y Liu; D el-Ashry; D Chen; I Y Ding; F G Kern
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

Review 6.  The neu-protein and breast cancer.

Authors:  C R De Potter; A M Schelfhout
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

7.  Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice.

Authors:  W J Muller; C L Arteaga; S K Muthuswamy; P M Siegel; M A Webster; R D Cardiff; K S Meise; F Li; S A Halter; R J Coffey
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

8.  Establishment and characteristics of two new human mammary carcinoma lines serially transplantable in nude mice.

Authors:  H Naundorf; I Fichtner; G J Saul; W Haensch; B Büttner
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 9.  Molecular biology of breast carcinoma.

Authors:  D el-Ashry; M E Lippman
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

10.  Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis.

Authors:  Yoshihiro Hayakawa; Stefania Rovero; Guido Forni; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.